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Small-particle Inhaled Corticosteroid as First-line or
Step-up Controller Therapy in Childhood Asthma
Willem M.C. van Aalderen, MD, PhDa, Jonathan Grigg, MDb, Theresa W. Guilbert, MD, MSc, Nicolas Roche, MD, PhDd,
Elliot Israel, MDe, Richard J. Martin, MDf, Gene Colice, MDg, Dirkje S. Postma, MD, PhDh, Elizabeth V. Hillyer, DVMi,
Anne Burden, MSci, Victoria Thomas, MSci, Julie von Ziegenweidti, and David Price, FRCGPi,j Amsterdam, The
Netherlands; London, United Kingdom; Cincinnati, Ohio; Paris, France; Boston, Mass; Denver, Colo; Washington, DC; Groningen,
The Netherlands; Cambridge and Aberdeen, United KingdomWhat is already known about this topic? Evidence from randomized controlled trials regarding asthma controller
therapies for children is limited, usually short-term, and often not generalizable to general practice, where most children
with asthma are managed.
What does this article add to our knowledge? Over 1 outcome year, small-particle inhaled corticosteroid (ICS) was
more effective than standard sizeeparticle ICS for children initiating or stepping up ICS therapy and as effective as adding
a long-acting b2-agonist in a ﬁxed-dose combination inhaler.
How does this study impact current management guidelines? These ﬁndings challenge asthma guidelines that
recommend adding a long-acting b2-agonist as the ﬁrst-line alternative for stepping up therapy when asthma is not
controlled by ICS monotherapy.BACKGROUND: Because randomized controlled trials of
established pediatric asthma therapies are expensive and difﬁcult to
perform, observational studies may ﬁll gaps in the evidence base.
OBJECTIVES: To compare the effectiveness of representative
small-particle inhaled corticosteroid (ICS) with that of standard
sizeeparticle ICS for children initiating or stepping up ICS
therapy for asthma (analysis 1) and to compare the effectiveness
of ICS dose step-up using small-particle ICS with adding long-
acting b2-agonist (LABA) to the ICS (analysis 2).
METHODS: These historical matched cohort analyses drew on
electronic medical records of children with asthma aged 5 to 11
years. Variables measured during 2 consecutive years (1
baseline year for confounder deﬁnition and 1 outcome year)
included risk-domain asthma control (no hospital attendance
for asthma, acute oral corticosteroids, or lower respiratory tract
infection requiring antibiotics) and rate of severe exacerbations
(asthma-related emergency, hospitalization, or oral
corticosteroids).
RESULTS: In the initiation population (n [ 797 in each
cohort), children prescribed small-particle ICS versus standard
sizeeparticle ICS experienced greater odds of asthma control
(adjusted odds ratio, 1.49; 95% CI, 1.10-2.02) and lower severe
exacerbation rate (adjusted rate ratio, 0.56; 95% CI, 0.35-0.88).aDepartment of Pediatric Respiratory Medicine and Allergy, Emma Children’s
Hospital AMC, Amsterdam, The Netherlands
bBlizard Institute, Queen Mary University London, London, UK
cCincinnati Children’s Hospital and Medical Center, Cincinnati, Ohio
dCochin Hospital Group, AP-HP, University of Paris Descartes (EA2511), Paris, France
eBrigham and Women’s Hospital and Harvard Medical School, Boston, Mass
fDepartment of Medicine, National Jewish Health and University of Colorado
Denver, Denver, ColoStep-up outcomes (n [ 206 in each cohort) were also
signiﬁcantly better for small-particle ICS, with asthma control
adjusted odds ratio of 2.22 (95% CI, 1.23-4.03) and exacerba-
tions adjusted rate ratio of 0.49 (95% CI, 0.27-0.89). The
number needed to treat with small-particle ICS to achieve 1
additional child with asthma control was 17 (95% CI, 9-107) for
the initiation population and 5 (95% CI, 3-78) for the step-up
population. Outcomes were not signiﬁcantly different for
stepped-up small-particle ICS dose versus ICS/LABA combina-
tion (n [ 185 in each cohort).
CONCLUSIONS: Initiating or stepping up the ICS dose with
small-particle ICS rather than with standard sizeeparticle ICS
is more effective and shows similar effectiveness to add-on
LABA in childhood asthma.  2015 The Authors. Published
by Elsevier Inc. on behalf of the American Academy of Allergy,
Asthma & Immunology. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/). (J Allergy Clin Immunol Pract
2015;3:721-31)
Key words: Asthma; Childhood; Small-particle beclomethasone;
Fluticasone; Inhaled corticosteroid; Long-acting b2-agonist;
Step-up therapygWashington Hospital Center and George Washington University School of Medi-
cine, Washington, DC
hUniversity of Groningen, University Medical Center Groningen, Groningen, The
Netherlands
iResearch in Real Life, Ltd, Cambridge, UK
jAcademic Primary Care, University of Aberdeen, Aberdeen, UK
Data acquisition and analyses were funded by Teva Pharmaceuticals; access to data
from the Optimum Patient Care Research Database was cofunded by Research in
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TABLE I. Definitions of database-derived study outcome
measures
Risk-domain asthma control, includes all of the following:
1. No asthma-related* hospital attendance or admission, ED
attendance, out-of-hours attendance, or outpatient hospital
attendance, and
2. No GP consultation for lower respiratory tract infection requiring
antibiotics, and
3. No prescription for acute course of oral corticosteroids.
Overall control,† includes all of the following:
1. No asthma-related* hospital attendance or admission, ED
attendance, out-of-hours attendance, or outpatient hospital
attendance, and
2. No GP consultation for lower respiratory tract infection requiring
antibiotics, and
3. No prescription for acute course of oral corticosteroids, and
4. Average 2 puffs daily dose of SABA (salbutamol 200 mg/d or
terbutaline 500 mg/d)
Number of severe exacerbations,z deﬁned as any of the following:
1. Asthma-related* hospital attendance or admission or ED
attendance, or
2. Acute course of oral corticosteroids
Number of clinical exacerbations,z deﬁned as any of the following:
1. Asthma-related* hospital attendance or admission or ED attendance,
or
2. GP consultation for lower respiratory tract infection requiring an-
tibiotics, or
3. Acute course of oral corticosteroids
Treatment stability, includes all of the following:
1. Risk-domain asthma control (see above) and
2. No additional therapy after the index date as
a. increased ICS dose (by 50%), or
b. use of additional therapy as LABA, LTRA, or theophylline
Respiratory hospitalizations, deﬁned as
 hospitalizations with an asthma Read code þ uncoded hospitaliza-
tions occurring within a 7-d window (either side of the
hospitalization date) of a lower respiratory tract Read code
Mean daily ICS dose during the baseline and the outcome year, deﬁned as
 number of days supply of ICS divided by 365
ED, Emergency department; LTRA, leukotriene receptor antagonist.
*Asthma-related events in the database included all events with a lower respiratory
tract code, including all asthma codes and lower respiratory tract infection codes.
†Overall control was not an outcome measure in the small-particle ICS step-up vs
add-on LABA comparisons (analysis 2).
zFor the exacerbation deﬁnitions, any criteria occurring within 2 wk of each other are
counted as 1 exacerbation.
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VAN AALDEREN ETAL 723available from RCTs.7 Here, we report the results of 2 obser-
vational analyses, using routinely collected health care data,
designed to evaluate the effectiveness of 1-year controller therapy
for managing several clinically common situations in children
with asthma.
The objective of analysis 1 was to compare outcomes in children
after a ﬁrst prescription or a stepped-up dose of either a small-
particle ICS or a standard sizeeparticle ICS. We chose small-
particle beclomethasone and ﬂuticasone for comparison for
several reasons. These 2 ICS are the most widely used in the United
States today. In previous observational studies of adults, we found
that small-particle beclomethasone (ICS particles with median mass
aerodynamic diameter of 1.1 mm) is prescribed for asthma at
signiﬁcantly lower doses, but shows effectiveness over 1 year similar
to or better than that of ﬂuticasone (median mass aerodynamic
diameter, 2.4-3.2 mm, depending on formulation).8-10 Formula-
tions of small-particle ICS may be particularly relevant to the
treatment of children with asthma because of children’s physical
size (smaller airways than those of adults), as well as the association
of peripheral, small airways dysfunction with uncontrolled
asthma.11,12 In adults, small-particle beclomethasone has greater
and more uniform lung deposition, reaching both large and small
airways, than does larger-particle ICS.13-15 In children with asthma,
the lung deposition of small-particle ICS ranges from means of
37% to 55% of ex-actuator dose, depending on age and inhaler
device.16,17 For young children (ages 3-7 years), 1 month’s treat-
ment with small-particle beclomethasone administered using a
valved holding chamber signiﬁcantly decreased bronchial hyper-
responsiveness.18 In a small study, 20 children (ages 5-14 years)
with stable, moderate asthma experienced improvements in lung
function after being switched from standard ICS to small-particle
beclomethasone.19 Two small randomized comparative trials
failed to demonstrate signiﬁcant differences in effectiveness be-
tween small-particle beclomethasone and ﬂuticasone for
children.20,21
The objective of our analysis 2 was to compare the effec-
tiveness of stepping up asthma therapy by increasing the ICS
dose as a small-particle ICS versus adding a long-acting b2-
agonist (LABA) to the ICS in ﬁxed-dose combination or
separate inhalers. A recent RCT and meta-analyses of previous
RCTs comparing add-on LABA with increased ICS dose for
children have been inconclusive4,22 or report similar out-
comes23 with these 2 step-up strategies; however, the ICS
studied were all larger-particle formulations (budesonide and
ﬂuticasone).METHODS
Analyses and patients
These matched cohort analyses drew on anonymized clinical data
(1997 through January 2011) contained in 2 UK primary care
electronic databases: the General Practice Research Database, now
part of the National Health Service Clinical Practice Research
Datalink, and the Optimum Patient Care Research Database, pre-
viously well-described (see this article’s Online Repository at www.
jaci-inpractice.org).9,24-26 The study was done to standards sug-
gested for observational studies, including an independent steering
committee (not remunerated for participation), use of an a priori
analysis plan, and well-maintained and monitored study databases.27
Children’s characteristics were cross-referenced between the 2 data
sets to avoid duplication.We studied 2 consecutive years of data for each eligible child,
aged 5 to 11 years at the time of the index prescription: a baseline
year preceding the index prescription date, included for deﬁning
potential baseline confounders, followed by an outcome year. We
required a recorded asthma diagnosis in the database or evidence of
active asthma, deﬁned as 2 or more prescriptions for asthma therapy
(controller or reliever) during the baseline year. In addition, during
the outcome year, children had to have received at least 1 asthma
prescription in addition to the index prescription. Children were
excluded from the study for an ever-diagnosis of any chronic res-
piratory disease other than asthma or a baseline year prescription for
maintenance oral corticosteroid therapy or an ICS/LABA combi-
nation inhaler.
For analysis 1 comparing small-particle and standard sizeeparticle
ICS, we included children prescribed their ﬁrst ICS (initiation popu-
lation) or increased ICS dose (step-up population) as beclomethasone
TABLE II. Baseline characteristics of children in the small-particle ICS and standard size-particle ICS cohorts (analysis 1)
Characteristic
Initiation population Step-up population
Small-particle ICS
(n [ 797)
Standard SP ICS
(n [ 797) P value*
Small-particle ICS
(n [ 206)
Standard SP ICS
(n [ 206) P value*
Sex: male† 455 (57.1) 455 (57.1) NA 124 (60.2) 124 (60.2) NA
Age at index date (y),† mean  SD 7.7  2 7.7  2 NA 7.5  2.1 7.5  2.1 NA
Year of index prescription,† median (IQR) 2004 (2002-2006) 2003 (2001-2005) <.001 2005 (2003-2007) 2005 (2002-2007) <.001
Recorded comorbidityz
Possible atopy 558 (70.0) 574 (72.0) .37 159 (77.2) 161 (78.2) .81
Rhinitis diagnosis/Rx 140 (17.6) 202 (25.3) <.001 42 (20.4) 50 (24.3) .34
Eczema diagnosis/Rx 557 (69.9) 554 (69.5) .87 153 (74.3) 160 (77.7) .43
Preschool wheeze diagnosis 74 (13.3) 68 (12.1) .83 46 (30.1) 54 (35.1) .76
Preschool asthma diagnosis/Rx 296 (48.8) 293 (48.0) .95 120 (67.0) 128 (75.7) .14
Risk-domain asthma control 655 (82.2) 656 (82.3) .93 160 (77.7) 160 (77.7) NA
Overall control 576 (72.3) 579 (72.6) .79 87 (42.2) 87 (42.2) NA
Spacer device prescribed 232 (29.1) 233 (29.2) .95 88 (42.7) 78 (37.9) .29
Mean daily SABA dose (mg/d)†
0 325 (40.8) 325 (40.8) 3 (1.5) 3 (1.5)
1-100 165 (20.7) 165 (20.7) 42 (20.4) 34 (16.5)
101-200 208 (26.1) 208 (26.1) .18 63 (30.6) 71 (34.5) .11
201-400 84 (10.5) 77 (9.7) 66 (32.0) 59 (28.6)
>400 15 (1.9) 22 (2.8) 32 (15.5) 39 (18.9)
Median (IQR) daily ICS dose (mg/d)x NA NA — 55 (27e82) 55 (25e82) .57
Last ICS dose before the index date (mg/d)†,x NA NA —
1-99 40 (19.4) 44 (21.4)
100-199 147 (71.4) 143 (69.4) .62
200 19 (9.2) 19 (9.2)
Severe exacerbations†
0 743 (93.2) 743 (93.2) NA 174 (84.5) 174 (84.5) NA
1 49 (6.1) 49 (6.1) 27 (13.1) 27 (13.1)
2 5 (0.6) 5 (0.6) 5 (2.4) 5 (2.4)
Asthma consultation and no oral corticosteroids†
0 400 (50.2) 400 (50.2) 64 (31.1) 64 (31.1)
1 297 (37.3) 297 (37.3) .15 75 (36.4) 75 (36.4) .11
2 82 (10.3) 75 (9.4) 45 (21.8) 36 (17.5)
3 18 (2.3) 25 (3.1) 22 (10.7) 31 (15.0)
IQR, Interquartile range; NA, not applicable; Rx, therapy; standard SP, standard sizeeparticle.
Data are presented as n (%) except otherwise indicated.
*Matched cohorts were compared using conditional logistic regression.
†Matching variable (year of index prescription matched  4 y; for details, please see this article’s Online Repository at www.jaci-inpractice.org).
zPossible atopywas deﬁned as any 1 or more of the following: recorded rhinitis diagnosis, rhinitis therapy, eczema diagnosis, eczema therapy. Preschool wheeze was captured through
database coding; concomitant rhinitis, eczema, and preschool asthma were captured through database-coded diagnosis or therapy for same. Preschool was deﬁned as age 1 to 3 y.
xThe doses of ICS were standardized to equivalence with small-particle beclomethasone and ﬂuticasone; thus, doses of large-particle beclomethasone and budesonide were
halved.
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724 VAN AALDEREN ETALdipropionate hydroﬂuoroalkane (QVAR; Teva UK Ltd, Eastbourne,
East Sussex, UK), of interest to the study sponsor and the only small-
particle ICS available in the United Kingdom at the time, or ﬂutica-
sone propionate (hydroﬂuoroalkane or chloroﬂuorocarbon formulation;
Flixotide; GlaxoSmithKline UK Ltd, Brentford, Middlesex, UK) by
pressurized metered-dose inhaler (pMDI). Children in the step-up
population were prescribed an ICS (any type) during the baseline year
and on the index date were prescribed an increase of 50% ormore in the
ICS dose as either small-particle ICS or standard sizeeparticle ICS.
For analysis 2 (step-up comparisons of small-particle ICS vs add-
on LABA), eligible children prescribed ICS during the baseline year
by pMDI or breath-actuated metered-dose inhaler were stepped up
to 1 of 3 options: 1) an increase of 50% or more in the ICS dose as
small-particle beclomethasone by pMDI or breath-actuated inhaler
(ICS step-up cohort); 2) addition of LABA, with no change in theICS dose, via ﬁxed-dose ICS/LABA combination inhaler (ICS/LABA
combination cohort) as either ﬂuticasone propionate/salmeterol
xinafoate (Seretide; GlaxoSmithKline UK Ltd, Brentford, Mid-
dlesex, UK) or budesonide/formoterol fumarate dihydrate (Symbi-
cort; AstraZeneca Ltd, Luton, Bedfordshire, UK); or 3) addition of
LABA by separate inhaler, with no change in the ICS drug, dose, or
inhaler (separate ICS þ LABA cohort).
Study end points
Composite measures to evaluate asthma-related outcomes, used in
our previous studies,8,9,26 are deﬁned in detail in Table I. In brief,
risk-domain asthma control (asthma control) was deﬁned as no hospital
attendance for asthma, acute oral corticosteroid course, or general
practice (GP) consultation for lower respiratory tract infection
requiring antibiotics; the latter criterion was included because, in
TABLE III. Outcome-year results for matched cohorts prescribed small-particle ICS or standard SP ICS for first-line or step-up therapy
(analysis 1)
Outcome
Initiation population Step-up population
Small-particle ICS (n [ 797) Standard SP ICS (n [ 797) Small-particle ICS (n [ 206) Standard SP ICS (n [ 206)
Risk-domain asthma control 702 (88.1) 667 (83.7) 182 (88.3) 156 (75.7)
Overall control 488 (61.2) 441 (55.3) 88 (42.7) 83 (40.3)
Treatment stability 631 (79.2) 545 (68.4) 156 (75.7) 134 (65.0)
Severe exacerbation
0 759 (95.2) 735 (92.2) 189 (91.7) 170 (82.5)
1 29 (3.6) 54 (6.8) 14 (6.8) 29 (14.1)
2 9 (1.1) 8 (1.0) 3 (1.5) 7 (3.4)
Clinical exacerbation
0 706 (88.6) 671 (84.2) 182 (88.3) 158 (76.7)
1 71 (8.9) 104 (13.0) 19 (9.2) 32 (15.5)
2 20 (2.5) 22 (2.8) 5 (2.4) 16 (7.8)
Disaggregated results of composite measures P value* P value*
1 asthma-related hospital attendance 10 (1.3) 10 (1.3) 1.0 2 (1.0) 7 (3.4) .12
1 acute course of oral corticosteroids 36 (4.5) 59 (7.4) .057 17 (8.3) 35 (17.0) .013
1 GP consultation for LRTI requiring antibiotic 57 (7.2) 73 (9.2) .13 12 (5.8) 20 (9.7) .11
Mean >2 puffs daily SABA 261 (32.7) 297 (37.3) .041 110 (53.4) 109 (52.9) .92
Increase in ICS dose or additional therapy 89 (11.2) 157 (19.7) <.001 30 (14.6) 31 (15.0) .88
LRTI, Lower respiratory tract infection; standard SP, standard sizeeparticle.
Data are presented as n (%).
*Conditional logistic regression.
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tory tract infection.28,29 The deﬁnition of overall control included
asthma control plus limited reliever use (daily average of 2 puffs of
short-acting b2-agonist [SABA], deﬁned as albuterol 200 mg/d or
terbutaline 500 mg/d, calculated as the dispensed amount divided
by 365).
Severe exacerbations were deﬁned according to American Thoracic
Society/European Respiratory Society criteria (asthma-related emer-
gency or hospitalization or oral corticosteroids).30 A second extended
deﬁnition of clinical exacerbation, developed with the guidance of
respiratory clinicians, included the additional criterion of a GP
consultation for lower respiratory tract infection as deﬁning an exac-
erbation. Another composite measure, treatment stability, was deﬁned
as risk-domain asthma control plus no treatment change (Table I).
Statistical analysis
Composite outcome measures and analyses were prespeciﬁed
according to standard operating procedures of the research group31
(see full details in this article’s Online Repository at www.jaci-
inpractice.org). The analyses were carried out using IBM SPSS
Statistics version 19 (SPSS Statistics, IBM, Somers, NY), SAS ver-
sions 9.2 and 9.3 (SAS Institute, Marlow, Buckinghamshire, UK),
and Microsoft Excel 2007 (Microsoft, Bellevue, Wash); statistically
signiﬁcant results were deﬁned as P < .05.
To minimize potential confounding by baseline differences be-
tween treatment cohorts, we matched children sequentially on de-
mographic characteristics (sex then age) and several clinically
important indicators of baseline asthma severity (sequence described
in this article’s Online Repository at www.jaci-inpractice.org).
Children in the step-up cohorts of analysis 1 and those in analysis 2
were also matched on the last ICS dose prescribed before the index
prescription. We calculated the mean daily ICS dose during baseline
as the dispensed amount divided by 365, standardizing the dose tothat of small-particle beclomethasone (Table I). Matching ratios
were chosen to maximize patient numbers and thus statistical power
for the comparisons (see this article’s Online Repository at www.jaci-
inpractice.org).
We evaluated all baseline and outcome variables using summary
statistics. Conditional logistic regression was used to quantify base-
line differences between matched cohorts. Potential confounding
factors were examined for colinearity and clinical importance to
select those used as potential confounders in the regression modeling
of outcomes; a detailed list is provided in this article’s Online Re-
pository at www.jaci-inpractice.org. Variables that differed between
treatment cohorts at P < .10 were considered as potential con-
founding factors, as well as baseline variables predictive of outcomes
in multivariate analyses at P < .05.
The odds of achieving risk-domain asthma control during the
outcome year were compared between matched treatment cohorts
using conditional binary logistic regression models. Asthma control
status was used as the dependent variable, with treatment and potential
confounding factors as explanatory variables. Similar methods were
used to calculate the adjusted odds ratio (adjOR) for overall control
(analysis 1 only) and treatment stability. Where a signiﬁcant difference
was found between treatment cohorts in the primary outcome of risk-
domain asthma control, we also calculated the difference in proportions
achieving control between treatment cohorts (using the same condi-
tional binary logistic regression model; with 95% CI) and the number
needed to treat (NNT) for 1 additional child to achieve control (the
inverse of the difference in proportions; with 95% CI) to better
quantify the difference in treatment effect between cohorts. To account
for multiple comparisons in the primary outcomes, a false-discovery
rate controlling procedure was used (for description, see this article’s
Online Repository at www.jaci-inpractice.org).32
The total number of severe exacerbations in the outcome year
was compared between treatment cohorts using a conditional
FIGURE 1. AdjORs and adjRRs comparing treatment cohorts during 1 outcome year. A, Initiation asthma therapy comparing small-particle
ICS vs standard sizeeparticle ICS (standard sizeeparticle ICS set at odds/rate ¼ 1.0). LRTI, Lower respiratory tract infection. Adjusted for
the following confounders: *Consultation for LRTI requiring antibiotic (yes/no). †Asthma control status, number of asthma/allergy pre-
scriptions; zLABA use (yes/no) and number of noneasthma-related consultations. xRhinitis diagnosis, year of index date. #Consultation
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erbation rates. The model used empirical standard errors (for
more conservative CI estimations), and adjustments were made
for potential baseline confounders. The adjusted rate ratios
(adjRRs) for clinical exacerbations and hospitalizations were
calculated in a similar fashion.
For children initiating ICS, we conducted several subgroup ana-
lyses to further examine factors that could be inﬂuencing the out-
comes of therapy, including spacer prescriptions and age grouped as
5 to 6 and 7 to 11 years (described in this article’s Online Repository
at www.jaci-inpractice.org). For the step-up comparisons of small-
particle ICS versus add-on LABA, we calculated the total b2-
agonist load (SABA þ LABA) in terms of total hours of coverage (see
this article’s Online Repository at www.jaci-inpractice.org).
RESULTS
Identiﬁcation of children in the data sets and the results of
cohort matching are depicted in Figures E1-E4 in this article’s
Online Repository at www.jaci-inpractice.org.
Analysis 1: Small-particle ICS versus standard
sizeeparticle ICS as first-line or step-up ICS therapy
Initiation population. The 2 initiation cohorts were well
matched at baseline for composite measures of asthma severity
(Table II; see Table E1 in this article’s Online Repository at
www.jaci-inpractice.org). A signiﬁcant difference in median in-
dex date was minor and likely not clinically meaningful.
Signiﬁcantly fewer children in the small-particle ICS cohort had
rhinitis or were receiving rhinitis therapy (18% vs 25% for
standard sizeeparticle ICS; P < .001); rates of possibly atopy
were similar (70% vs 72%, respectively; Table II). There were
signiﬁcant mean  SD differences in index date doses (167  85
vs 221  157 mg/d for small-particle vs standard sizeeparticle
ICS; P < .001), and fewer children in the small-particle ICS
cohort were prescribed an ICS dose of 400 mg/d or more (7.4%
vs 15.6% for standard sizeeparticle ICS; see Figure E5, A, in this
article’s Online Repository at www.jaci-inpractice.org).
During the outcome year (Table III), the odds of achieving
risk-domain asthma control were signiﬁcantly greater for children
initiating small-particle ICS than for those initiating standard
sizeeparticle ICS therapy (adjOR, 1.49; 95% CI, 1.10-2.02;
Figure 1, A). The adjusted difference in proportions achieving
asthma control (small-particle ICS vs standard sizeeparticle ICS)
was 0.06 (95% CI, 0.01-0.11; adjusted for baseline GP
consultation for lower respiratory tract infection resulting in an
antibiotic prescription). The NNT to achieve 1 additional childfor LRTI requiring antibiotic, rhinitis diagnosis, year of index date.
ˇ
Rh
asthma therapy comparing small-particle ICS vs standard sizeepa
Adjusted for the following confounders: *Acetaminophen prescriptio
vague). †Number of SABA prescriptions. zNumber of asthma/allergy
#Number of asthma consultations. ^Number of ICS prescriptions and
comparing step-up with increased dose of small-particle ICS vs add-on
rate ¼ 1.0). For details of confounding factors examined, see this artic
following confounders: *No significant effects (unadjusted odds ratio
consultations, emergency department attendance for asthma or lower
care consultations, average SABA daily dose, number of acute course
respiratory tract reasons; xGastroesophageal reflux disease diagnosis, n
for LRTI; #Definite and probable asthma-related inpatient admissions,with asthma control using small-particle ICS was 17.0 (95% CI,
9.3-107.2).
In addition, children in the small-particle ICS cohort had
signiﬁcantly greater odds of overall asthma control (adjOR, 1.30;
95% CI, 1.04-1.62) and signiﬁcantly lower exacerbation rates
(for both deﬁnitions; severe exacerbations adjRR, 0.56; 95% CI,
0.35-0.88) than did those in the standard sizeeparticle ICS
cohort, also with false-discovery rate correction. Children pre-
scribed small-particle ICS had signiﬁcantly greater odds of
treatment stability, driven by signiﬁcantly lower rates of therapy
change (Table III; see Table E2 in this article’s Online
Repository at www.jaci-inpractice.org; Figure 1, A). Respiratory-
related hospitalization rates were low and comparable between
treatment cohorts.Subgroup analyses: Initiation population. A total of
465 children in the standard sizeeparticle ICS cohort were
prescribed a spacer device in the baseline and/or outcome year,
but of the 465 matched children prescribed small-particle ICS,
only 69% were prescribed a spacer. Outcomes for this subgroup
paralleled those for the full matched initiation cohorts, with
adjusted odds of asthma control signiﬁcantly higher (risk-domain
asthma control adjOR, 1.81; 95% CI, 1.24-2.65) and relative
exacerbation rates signiﬁcantly lower (severe exacerbation adjRR,
0.53; 95% CI, 0.29-0.98) for the small-particle ICS subcohort
(see Table E3 in this article’s Online Repository at www.jaci-
inpractice.org).
Results of unmatched subgroup analyses of children with no
rhinitis or rhinitis therapy and those without exacerbations
during the baseline year were consistent with the main ﬁndings
(see Online Repository text and Table E3).
Results of matched cohort analyses by age group found that
outcomes with small-particle ICS remained signiﬁcantly better
(compared with standard sizeeparticle ICS) for 5- to 6-year-old
children but were comparable with standard sizeeparticle ICS
for the 7- to 11-year-old children (Online Repository). Figure E6
(in this article’s Online Repository at www.jaci-inpractice.org)
suggests greater variability in ICS response in younger children
and the standard sizeeparticle ICS cohort.Step-up population. The 2 step-up cohorts were well
matched at baseline (Table II; Table E1). Statistically signiﬁcant
differences in mean index date dose (224 [95] vs 262 [170] mg/
d for small-particle vs standard sizeeparticle ICS; P < .001) were
likely not clinically signiﬁcant (Figure E5, B).initis diagnosis, acetaminophen prescription (yes/no). B, Step-up
rticle ICS (standard sizeeparticle ICS set at odds/rate ¼1.0).
n, lower respiratory tract-related inpatient admissions (including
prescriptions (categorized). xNumber of asthma consultations.
Charlson comorbidity index score. C, Adjusted outcome measures
LABA in fixed-dose combination with ICS (ICS/LABA set at odds/
le’s Online Repository at www.jaci-inpractice.org. Adjusted for the
). †Number of antibiotic prescriptions for LRTI, number of asthma
respiratory tract reasons. zYear of index date, number of primary
s of oral corticosteroids, inpatient admissions for asthma or lower
umber of asthma consultations, number of antibiotic prescriptions
year of index date.
TABLE IV. Baseline characteristics of children in the small-
particle ICS step-up and combination ICS/LABA cohorts
(analysis 2)
Characteristic
ICS step-up vs ICS/LABA combination
ICS
step-up
(n [ 185)
ICS/LABA
combination
(n [ 185) P value*
Sex: male† 114 (61.6) 114 (61.6) NA
Age at index date (y),† mean
 SD
8.3  1.9 8.3  1.9 NA
Recorded comorbidityz
Possible atopy 148 (80.0) 143 (77.3) .54
Rhinitis diagnosis/Rx 48 (25.9) 46 (24.9) .82
Eczema diagnosis/Rx 135 (73.0) 131 (70.8) .66
Preschool wheeze
diagnosis
70 (37.8) 62 (33.5) .39
Preschool asthma
diagnosis/Rx
94 (50.8) 98 (53.0) .66
Risk-domain asthma control† 129 (69.7) 129 (69.7) NA
Spacer device prescribed 70 (37.8) 85 (45.9) .12
Mean daily SABA dose (mg/d)†
0-100 33 (17.8) 24 (13.0)
101-200 58 (31.4) 67 (36.2)
201-400 66 (35.7) 66 (35.7) .29
401-800 20 (10.8) 22 (11.9)
>800 8 (4.3) 6 (3.2)
Median (IQR) daily ICS dose
(mg/d)x
55 (27-110) 55 (27-110) .26
Last ICS dose before the index date (mg/d)†,x
1-50 0 (0.0) 0 (0.0)
51-100 107 (57.8) 107 (57.8) NA
101-200 78 (42.2) 78 (42.2)
Severe exacerbations
0 147 (79.5) 144 (77.8)
1 27 (14.6) 28 (15.1) .90
2 6 (3.2) 12 (6.5)
3 5 (2.7) 1 (0.5)
Asthma consultation/no oral corticosteroids†
0 61 (33.0) 61 (33.0)
1 61 (33.0) 61 (33.0) .09
2 37 (20.0) 28 (15.1)
3 26 (14.1) 35 (18.9)
IQR, Interquartile range; NA, not applicable; Rx, therapy; standard SP, standard
sizeeparticle.
Data are presented as n (%) except otherwise indicated.
*Matched cohorts were compared using conditional logistic regression.
†Matching variable (for details, please see this article’s Online Repository at www.
jaci-inpractice.org).
zPossible atopy was deﬁned as any 1 or more of the following: recorded rhinitis
diagnosis, rhinitis therapy, eczema diagnosis, eczema therapy. Preschool wheeze was
captured through database coding; concomitant rhinitis, eczema, and preschool
asthma were captured through database-coded diagnosis or therapy for same.
Preschool was deﬁned as age 1 to 3 y.
xThe doses of ICS were standardized to equivalence with small-particle beclome-
thasone and ﬂuticasone; thus, doses of large-particle beclomethasone and budesonide
were halved.
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their ICS therapy as small-particle ICS had signiﬁcantly greater
odds of achieving risk-domain asthma control. The adjusted
difference in proportions achieving asthma control (small-particle
ICS vs standard sizeeparticle ICS) was 0.21 (95% CI, 0.10-
0.40; adjusted for baseline acetaminophen prescriptions and
baseline lower respiratory tract-related inpatient admissions). The
NNT to achieve 1 additional child with asthma control using
small-particle ICS was 4.8 (95% CI, 2.5-77.8).
Children prescribed small-particle ICS had signiﬁcantly
lower exacerbation rates (both deﬁnitions) than did children
stepping up their ICS therapy as standard sizeeparticle ICS, as
well as signiﬁcantly greater odds of treatment stability (at the
5% level; Figure 1, B). Results for overall control, incorporating
SABA use, were comparable for the 2 cohorts, as were lower
respiratory tract-related hospitalization rates during the outcome
period (Figure 1, B).
Analysis 2: Small-particle ICS step-up versus add-on
LABA in ICS/LABA combination inhaler
After 1:1 matching, statistically signiﬁcant baseline differences
between the ICS step-up and ICS/LABA combination cohorts
were minor (Table IV; see Table E4 in this article’s Online
Repository at www.jaci-inpractice.org).
Median (interquartile range) ICS doses prescribed at the index
date were 200 (200-400) mg/d for the ICS step-up and 100 (100-
200) mg/d for the ICS/LABA combination cohort (P < .001 for
the comparison). There were no signiﬁcant differences in the
adjusted outcome measures between ICS step-up and ICS/LABA
combination cohorts (Figure 1, C). However, for the ICS/LABA
combination cohort, change in therapy was signiﬁcantly more
common, and the total b2-agonist coverage (LABA plus SABA)
was signiﬁcantly greater (Table V; see Table E5 and Figure E7,
A, in this article’s Online Repository at www.jaci-inpractice.org).
The ICS step-up and separate ICS þ LABA cohorts were
similar after 1:2 matching (see Tables E4 and E6 in this article’s
Online Repository at www.jaci-inpractice.org). The odds of
treatment stability were higher for ICS step-up, but the odds of
asthma control and exacerbation rates were comparable between
cohorts (see Table E7 and Figure E8 in this article’s Online
Repository at www.jaci-inpractice.org). Total b2-agonist coverage
was greater for the separate ICS þ LABA cohort (Table E5;
Figure E7, B).
DISCUSSION
The observational design of these 2 analyses provides direct
comparative evidence, not currently available from RCTs, about
clinically relevant outcomes using different treatment approaches
to common clinical situations in children with asthma. We found
that the rate of severe exacerbations among children with asthma
aged 5 to 11 years prescribed small-particle ICS was signiﬁcantly
lower than that for children prescribed standard sizeeparticle ICS.
both for those initiating ICS (adjRR, 0.56) and for those stepping
up the ICS dose (adjRR, 0.49). Moreover, the adjusted odds of the
risk-domain composite measure of asthma control were signiﬁ-
cantly greater for children initiating small-particle ICS, as well as
for children stepping up the dose of small-particle ICS, when
compared with those for children initiating or stepping up the
dose of standard sizeeparticle ICS. The NNTs to achieve 1
additional child with asthma control using small-particle ICS were
17 and 5 for the initiation and step-up populations, respectively.In the comparison of step-up strategies in analysis 2, increasing
small-particle ICS dose was comparable to adding LABA in a
combination ICS/LABA inhaler with regard to both asthma
control and exacerbation measures.
TABLE V. Outcome-year results for matched cohorts prescribed
increased ICS dose of small-particle ICS or combination ICS/LABA
(analysis 2)
Outcome
ICS step-up vs ICS/LABA combination
ICS dose
step-up
(n [ 185)
ICS/LABA
combination
(n [ 185)
Risk-domain asthma control 148 (80.0) 146 (78.9)
Treatment stability 132 (71.4) 118 (63.8)
Severe exacerbation
0 162 (87.6) 161 (87.0)
1 17 (9.2) 14 (7.6)
2 6 (3.2) 10 (5.4)
Clinical exacerbation
0 151 (81.6) 148 (80.0)
1 24 (13.0) 25 (13.5)
2 10 (5.4) 12 (6.5)
Disaggregated results of
composite measures P value*
1 asthma-related hospital
attendance
1 (0.5) 2 (1.1) .57
1 acute course of oral
corticosteroids
22 (11.9) 23 (12.4) .52
1 GP consultation for LRTI
requiring antibiotic
19 (10.3) 19 (10.3) 1.0
Mean >2 puffs daily SABA 110 (59.5) 98 (53.0) .11
Increase in ICS dose or additional
therapy
29 (15.7) 43 (23.2) .002
LRTI, Lower respiratory tract infection; standard SP, standard sizeeparticle.
Data are n (%) unless otherwise stated.
*Conditional logistic regression.
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studies,8,9 greater differences were evident in outcomes favoring
small-particle ICS relative to standard sizeeparticle ICS, for
both initiation and step-up cohorts. There are few other studies
comparing small- and standard sizeeparticle ICS for children
with asthma. A Cochrane analysis compared ciclesonide with
other ICS for children but was inconclusive.3 The Cochrane
analysis that compared small-particle hydroﬂuoroalkane-beclo-
methasone and ﬂuticasone for children with asthma was limited
because only 2 studies were found.2 Robroeks et al20 reported
no difference between 12-week therapy with small-particle
beclomethasone or ﬂuticasone in either anti-inﬂammatory ef-
fects or clinical outcomes for 33 children with asthma in a small
crossover study, although children at study start had normal
lung function and generally well-controlled asthma. van Aal-
deren et al12,21 showed that small-particle beclomethasone and
ﬂuticasone had similar effects on lung function and overall
asthma control in an 18-week ICS step-down study in 280
children aged 5 to 12 years with mild-to-moderate asthma.
Neither study examined comparative effects of these 2 ICS on
exacerbations in children over a 1-year period. The present
analyses add to these shorter-term, smaller studies and
demonstrate the value of pragmatic research for understanding
asthma therapies in children.
The pattern of results according to the ICS dose during the
outcome year suggests that the odds of risk-domain asthma
control were better for children at lower doses of bothsmall-particle and standard sizeeparticle ICS (depicted in
Figure E6). We found a similar pattern of results in a previous
US retrospective study,8 whereby adults with lower medication
possession ratio had better risk-domain asthma control and fewer
exacerbations. We speculate that this is because adherence with
ICS increases after exacerbations, as supported by previous
observational studies,33,34 and that patients whose asthma is well-
controlled may be less likely to take their ICS regularly.
In our subanalyses, small-particle ICS offered an advantage
especially in younger children (5-6 years old vs 7-11 years old).
The reason for this additional advantage is unknown, but Amirav
and Newhouse35 have speculated that better outcomes with ICS
in young children will be achieved using formulations with
smaller particle size. We also found no difference from the main
ﬁndings in comparative results when standard sizeeparticle ICS
was given under ideal circumstances with a spacer (the small-
particle ICS subanalysis cohort was not required to have a
spacer, and 31% did not). This differs from the accepted view
that spacer use is necessary to achieve improved lung deposition
in children prescribed a pMDI.36 Deposition studies in children
as young as 5 to 7 years have conﬁrmed that even without a
spacer, 38% or more of a single inhalation of small-particle
beclomethasone reaches the lungs. Furthermore, good lung
deposition (>30%) occurs with small-particle beclomethasone
even in patients who are unable to precisely coordinate inhalation
and actuation of a pMDI.13
In analysis 2 comparing the stepped-up dose of small-particle
ICS versus adding LABA by ﬁxed-dose combination inhaler, we
found that the percentages of children meeting outcome mea-
sures improved substantially in both cohorts, without signiﬁcant
differences between cohorts in effectiveness. Although both UK
asthma management guidelines and US drug labeling recom-
mend the prescribing of ICS/LABA as ﬁxed-dose combination
inhalers for children and adolescent patients to ensure their
adherence to concomitant therapy,37,38 we found a substantial
number of children receiving ICS and LABA by separate in-
halers. Of potential interest, a novel ﬁnding in this analysis was
that the b2-agonist load over the 1-year outcome period was
signiﬁcantly lower, and shorter-acting, in the small-particle ICS
than in the ICS/LABA combination cohort.
Our ﬁndings that increasing the ICS dose for children with
uncontrolled asthma can provide clinically meaningful
improvement is supported by the work of Lemanske et al.23 In
their rigorously performed, National Institutes of Healthe
sponsored, randomized crossover trial assessing differential
responses to 3 step-up strategies for 165 children with un-
controlled asthma on low-dose ﬂuticasone, the best response
for most of the children was obtained with LABA step-up
therapy; however, many children also demonstrated best
response to ICS step-up.23 Response was measured over only
16 weeks in their study, and ﬂuticasone was administered as
the ICS. We can speculate, on the basis of the results of the
present study, that more children may have demonstrated a
best response to ICS step-up if a small-particle ICS had been
used as the ICS. Moreover, our longer-term ﬁndings provide
further information that calls into question the recommenda-
tions of UK and international asthma guidelines, which
identify add-on LABA as the ﬁrst-line alternative for stepping
up therapy when asthma is not controlled by ICS mono-
therapy.37,39 Properly designed RCTs might be of help to
further explore the ﬁndings reported here.
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effects of therapy, particularly growth. Information on height is
not routinely available from database sources, and height mea-
surements in daily practice are not performed using the rigorous
criteria of an RCT. Although linear growth could not be
measured in our study, recent RCTs found that daily use of
beclomethasone is associated with a decreased linear growth of
approximately 1 cm compared with the use of intermittent ICS
or leukotriene receptor antagonist; a similar pattern has been
found with regular use of other ICS.40-43
An important limitation of observational studies is the possi-
bility of unrecognized confounders. Although the matching
process is designed to reduce this possibility by comparing co-
horts of similar baseline asthma severity, we note that for the
initiation population in analysis 1, there were fewer children with
rhinitis, a factor that can inﬂuence asthma control, in the small-
particle cohort than in the standard sizeeparticle ICS cohort.
However, similar proportions of children in the 2 cohorts had
possible atopy, and the results of the no rhinitis subanalysis
supported the main ﬁndings.
As small-particle beclomethasone is not approved for use in
the United Kingdom for children younger than 12 years, it
might be argued that GPs prescribing this product would be
more knowledgeable about asthma. However, during the study
period, similar numbers of children in the data sets were initiated
on small-particle beclomethasone (w4%) and ﬂuticasone
(w6%). Two other observations argue against large differences
between the 2 physician groups in asthma management knowl-
edge: (1) similar (and low) proportions of children had recorded
peak expiratory ﬂow readings at baseline, and (2) socioeconomic
scores were similar for practices in which small-particle beclo-
methasone or ﬂuticasone was prescribed.
Strengths of the present analyses include the large numbers of
children, the capture of clinically relevant outcomes over a full
year for each child, and the consistency of ﬁndings across main
analyses and subanalyses. We matched, in addition to sex and
age, on all clinically reasonable indicators of baseline asthma
severity available in the database. Because the criteria were
applied sequentially, for example, ﬁrst on sex and then on age,
children were matched on age within the female and male
groupings. We believe that this matching approach is particularly
relevant to the study of children, for whom age is an important
factor; in addition, it enabled us to examine subgroups of pa-
tients who might interact with outcome, for example, the
youngest children with the smallest airways. This matching
approach differs from the use of propensity score matching,
which instead produces 2 cohorts with similar distributions of
multiple covariates used to construct the propensity score but not
paired patients precisely matched by age and sex.44
We limited the study to a comparison of small-particle
beclomethasone (the only small-particle ICS available in the
United Kingdom at the time) and ﬂuticasone, which is a larger-
particle ICS that is recommended for administration at the same
doses as small-particle beclomethasone.37,45,46 Thus, our con-
clusions are limited to the studied comparisons and are not
generalizable to other ICS. Additional studies, including pro-
spective pragmatic clinical trials, are needed to further investigate
the effectiveness of other small-particle ICS, such as ciclesonide,
for children with asthma.
In conclusion, we found that initiating or stepping up the dose
of ICS with a small-particle ICS is signiﬁcantly more effectivethan doing so with a standard sizeeparticle ICS, and has similar
effectiveness as add-on LABA for children with asthma treated in
primary care practice. The differential effects of small-particle
ICS versus standard sizeeparticle ICS were more pronounced
in children than in our previous adult studies8,9 and more pro-
nounced in the younger children than in the older children. We
cannot identify the factors associated with the beneﬁcial effect
but speculate that this is, in part, due to smaller particle size and
better ICS deposition in children with smaller airways.
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Our hypothesis for analysis 1 was that asthma-related out-
comes for children, as for adults, would be similar or better with
small-particle ICS, even when prescribed at lower doses, than
with standard sizeeparticle ICS. Our hypothesis for analysis 2
was that increasing the dose of small-particle ICS would be an
effective alternative for children with persistent asthma who
require more treatment than their initial ICS therapy.
The study was done to standards suggested for observational
studies, including an independent steering committee, use of an a
priori analysis plan, and well-maintained and monitored study
databases.E1-E3 The members of the steering committee are
practicing physicians working in different areas of respiratory
medicine who provide varied perspectives and guidance to
Research in Real Life (RiRL), functioning in complete intellec-
tual independence. The group comprises adult practitioners and
pediatricians because multiple studies are being conducted in
various populations. The steering committee members are not
paid for their participation but are reimbursed by RiRL for travel
to annual or biannual meetings to discuss multiple ongoing
studies that are being conducted by RiRL. The design of the
study, analyses and subanalyses, and manuscript represent
consensus work of this committee, all of whom are authors on
the article together with the research team at RiRL.
Although clinical trial registration was not required because
this was a noninterventional study, each of the analyses was
registered, as a separate study, with registered clinical trials reg-
istry numbers NCT01141439 and NCT01697722.
Data sources
The data sets we used contain anonymized primary care
medical records, data entered by health care providers during
patient consultations in the form of Read codes. The General
Practice Research Database is a large, well-regarded, and well-
validated primary care database containing anonymized medical
record data from subscribing practices throughout the United
Kingdom and used frequently for pharmacoepidemiological
researchE4-E7; it now forms part of the National Health Service
Clinical Practice Research Datalink, the English National Health
Service observational data and interventional research serv-
ice.E8,E9 The Optimum Patient Care Research Database is a
newer primary care database, established to rigorous standards,
that contains anonymous patient data, including both medical
records and patient-completed respiratory questionnaire results,
from more than 300 primary care practices subscribing to the
Optimum Patient Care respiratory review service.E10 The value
of this database information speciﬁcally for studying respiratory
diseases has been documented in numerous high-quality pub-
lications.E4-E12
The available data for this study spanned 1997 through
January 2011 and was approved for use by the General Practice
Research Database Independent Scientiﬁc Advisory Committee
and, for the Optimum Patient Care Research Database, by the
Trent Multi Centre Research Ethics Committee. The study
protocol was approved by the Anonymised Data Ethics Protocols
and Transparency Committee, the independent scientiﬁc advi-
sory committee for Optimum Patient Care.
Patients and outcomes
Allowed ICS therapies during the baseline year for step-up
cohorts included beclomethasone, budesonide, or ﬂuticasoneadministered by pMDI or breath-actuated inhaler. Small-particle
beclomethasone dipropionate hydroﬂuoroalkane (HFA) (QVAR;
Teva Pharmaceuticals) is labeled for administration to both adults
and children at half the daily dose of chloroﬂuorocarbon (CFC) or
larger-particle HFA-beclomethasone (Clenil Modulite; Chiesi Ltd,
Highﬁeld, Cheadle, UK) and at the same dose as HFA- or CFC-
ﬂuticasone propionate.E13,E14 Thus, we standardized ICS doses to
small-particle beclomethasone for the analyses, using a 1:1 ratio
for small-particle beclomethasone and ﬂuticasone, and for both
the latter a 1:2 dose ratio relative to budesonide and larger-particle
CFC- or HFA-beclomethasone. Heights and weights were not
routinely available in the data sets for all children.
Statistical analysis
For the small-particle ICS versus standard sizeeparticle ICS
comparison, the coprimary outcomes were risk-domain
asthma control and the total number of severe exacerba-
tions; for the small-particle ICS versus add-on LABA com-
parisons, the primary outcome was risk-domain asthma
control (see Table I in the main article). We used the false-
discovery rate controlling procedure of Benjamini and
LiuE15 to account for multiple comparisons in the primary
outcomes. This procedure modiﬁes the threshold (0.05) for
each comparison; with 2 coprimary outcomes, the “most
signiﬁcant” result is required to achieve signiﬁcance at the
2.5% level (P ¼ .025) while the second result is required to
achieve signiﬁcance at the 5% level (P ¼ .05).
For the patient population initiating ICS, we conducted
several subanalyses to further examine factors that could be
inﬂuencing the outcomes of therapy. We compared results with
small-particle ICS versus standard sizeeparticle ICS by age (5-6
years and 7-11 years); with use of a spacer for all children
receiving standard sizeeparticle ICS; for children with no rhinitis
diagnosis or therapy; and according to baseline asthma severity (0
or 1 exacerbation during the baseline year); the latter 2 sub-
analyses were conducted with unmatched patient data to increase
sample sizes. Patient numbers in the small-particle ICS and
standard sizeeparticle ICS step-up populations were insufﬁcient
to warrant subanalysis.
For the spacer subanalysis, we included all children in the
standard sizeeparticle ICS cohort with a spacer prescribed in
baseline and/or outcome year (total of 465 children). We then
compared these 465 children with their matches in the small-
particle ICS cohort; of that subgroup of matched children in
the small-particle ICS cohort, 69% were prescribed a spacer.
(Overall, however, approximately equal numbers of the 797
children in each of the initiation cohorts were prescribed a
spacer.)
For the step-up comparisons of small-particle ICS versus add-
on LABA, we calculated the total b2-agonist hours of coverage
(SABA þ LABA). We deﬁned albuterol 200 mg and terbutaline
500 mg as 2 puffs of SABA lasting 4 hours, whereas we deﬁned
b2-agonist coverage with LABA 2 puffs via pMDI or 1 puff via
dry powder inhaler as lasting 12 hours.
Different matching ratios were evaluated, and the 1:1 ratio
for the small-particle ICS versus standard sizeeparticle ICS
cohorts and the ICS dose step-up versus ICS/LABA combi-
nation cohorts and the 1:2 ratio for the ICS dose step-up
versus separate ICS þ LABA cohorts were chosen to maxi-
mize patient numbers and thus statistical power for the
comparisons.
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1. For small-particle ICS versus standard sizeeparticle ICS
initiation cohorts (analysis 1):
a. Sex
b. Age
c. Mean SABA daily dose during the baseline year (0, 1-100,
101-200, >200 mg/d)
d. Number of severe exacerbations during the baseline year
(0, 1, 2)
e. Number of asthma consultations without an oral cortico-
steroid prescription during the baseline year (0, 1, 2)
f. Year of index prescription (4 years)
2. For small-particle ICS versus standard sizeeparticle ICS step-
up cohorts (analysis 1):
a. Sex
b. Age
c. Last ICS dose prescribed before the index prescription (1-
100, 101-300, >300 mg/d)
d. Number of severe exacerbations during the baseline year
(0, 1, 2, 3)
e. Risk-domain asthma control status during the baseline year
(controlled/uncontrolled)
f. Mean SABA daily dose during the baseline year (0, 1-200,
>200 mg/d)
g. Number of asthma consultations without an oral cortico-
steroid prescription during the baseline year (0, 1, 2)
h. Year of index prescription (4 years)
3. For small-particle ICS versus add-on LABA cohorts (analysis 2):
a. Sex
b. Age
c. Last ICS dose prescribed before the index prescription (1-
50, 51-100, 101-200, 201-300, 301-400, >400 mg/d)
d. Mean SABA daily dose during the baseline year (0, 1-200,
201-400, >400 mg/d)
e. Number of asthma consultations without an oral cortico-
steroid prescription during the baseline year (0, 1, 2)
f. Risk-domain asthma control status during the baseline year
(controlled/uncontrolled)
Potential confounding factors considered:
Previous research in respiratory disease has identiﬁed a range
of potential confounders that can inﬂuence study outcomes.
These include a range of demographic, disease severity, treat-
ment, and comorbid factors.
Variables that differed between treatment cohorts at P < .10
were considered potential confounding factors, as well as baseline
variables predictive of outcomes in multivariate analyses at P <
.05. Spearman correlation coefﬁcients were calculated between all
potential confounders to determine strengths of linear relation-
ships between variables. The correlation coefﬁcients were
considered, in conjunction with clinical interpretation, to iden-
tify pairings of variables that could present collinearity issues at
the modeling stage. Scatter plots and error bars were used, if
necessary, to further investigate relationships.
We ﬁt the regression models separately for each subgroup.
However, because baseline differences across treatment arms
may have been different between full cohorts and subgroups, the
entire modeling process was repeated separately for each sub-
group to identify the unique adjustments needed for that
subgroup.Potential confounders examined, where available, at (or closest
to) the relevant index date for all children:
 Age
 Sex
 Height
 Weight
 Body mass index
 Lung function as percent predicted peak ﬂow readings before
the index date
Potential confounders examined regardless of when they
occurred relative to the index date:
 Date of ﬁrst asthma, other respiratory and allergy-related,
diagnosis (where known)
 Presence/absence of comorbid rhinitis (diagnosis ever and/or
prescriptions for rhinitis therapy in the baseline/outcome year)
 Presence/absence of comorbid eczema (diagnosis ever and/or
prescriptions for eczema therapy in the baseline/outcome year)
 Presence/absence of preschool wheeze (diagnosis ever)
 Presence/absence of preschool asthma (diagnosis ever and/or
prescriptions for asthma therapy in the baseline/outcome year)
 Presence of gastroesophageal reﬂux disease (diagnosis ever and/
or prescriptions for gastroesophageal reﬂux disease therapy in
the baseline/outcome year)
 Presence of cardiac disease (diagnosis ever and/or prescriptions
for cardiac drugs in the baseline/outcome year)
Potential confounders examined in the baseline year before the
index date:
 Where rhinitis is present, use of nasal corticosteroids for
treatment
 Other important unrelated comorbidities were expressed using
the Charlson comorbidity index
 Number of asthma consultations that did not result in a
prescription for an oral corticosteroid
 Number of hospital outpatient attendances where asthma was
recorded as the reason for referral
 Number of hospitalizations for asthma or possibly respiratory
related (a nonspeciﬁc hospitalization code and an asthma/
respiratory code within a 1-week window)
 Number of asthma-related emergency department visits
 Number of prescriptions for any antibiotic where the reason
for the prescription was lower respiratory tract infection
 Other medications, number of prescriptions for the following
in the year before the index date:
B Acetaminophen
B Nonsteroidal anti-inﬂammatory drugs
 Number of prescriptions for any respiratory therapy (split by
number of prescriptions for each)
 Number of asthma exacerbations
 Number of acute courses of oral corticosteroids
 Number of SABA prescriptions and average daily SABA dose
received (calculated on the basis of the total combined dose of
reﬁlled prescriptions and averaged over 365 days)
 Average ICS daily dose during the baseline year (calculated on
the basis of total combined dose of reﬁlled prescriptions and
averaged over 365 days) (step-up patients only)
 Last ICS dose prescribed before the index date (step-up pa-
tients only)
REFERENCES
E1. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC,
Vandenbroucke JP. The Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) statement: guidelines for reporting observational
studies. Lancet 2007;370:1453-7.
E2. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD,
Pocock SJ, et al. Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007;4:
e297.
E3. Price D, Hillyer EV, van der Molen T. Efﬁcacy versus effectiveness trials:
informing guidelines for asthma management. Curr Opin Allergy Clin
Immunol 2013;13:50-7.
E4. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the
General Practice Research Database: a systematic review. Br J Gen Pract 2010;
60:e128-36.
E5. Wood L, Martinez C. The general practice research database: role in phar-
macovigilance. Drug Saf 2004;27:871-81.
E6. Wong IC, Murray ML. The potential of UK clinical databases in enhancing
paediatric medication research. Br J Clin Pharmacol 2005;59:750-5.
J ALLERGY CLIN IMMUNOL PRACT
SEPTEMBER/OCTOBER 2015
731.e3 VAN AALDEREN ETAL Adherence to ICS therapy (step-up patients only)
 Spacer use/prescription
 Medication possession ratio (step-up patients only)
 Controller-to-reliever therapy ratio (step-up-population only)
 Oral candidiasis
RESULTS
Analysis 1: Small-particle ICS versus standard
sizeeparticle ICS as first-line or step-up ICS therapy
Unmatched versus matched baselines and results. For
analysis 1, we found that unmatched patients prescribed small-
particle ICS, as compared with standard sizeeparticle ICS, ten-
ded to be slightly older and to have later index prescription dates;
moreover, in the step-up population, those prescribed small-particle
ICS had less severe asthma, with a smaller percentage experiencing
multiple exacerbations during baseline (eg, 6% had 2 exacerba-
tions vs 12% in the unmatched standard sizeeparticle ICS cohort;
other data not shown). After matching, both treatment cohorts
tended to have less severe asthma than did the unmatched initiation
population (eg, 82% with risk-domain asthma control vs 77% of
the unmatched initiation population at baseline; other data not
shown).
The pattern of unmatched results during the outcome year
followed patterns for the matched cohorts, namely, better out-
comes for small-particle ICS (data not shown).
Initiation population. Coprimary outcomes remained sig-
niﬁcant after having controlled the false-discovery rate at the 0.05
level.
Initiation population subanalyses. Matched cohort sub-
analyses by age group found that outcomes with small-particle ICS
remained signiﬁcantly better (compared with standard sizeeparticle
ICS) for 5- to 6-year-old children initiating ICS (n ¼ 286 per
treatment cohort) but were comparable with standard sizeeparticle
ICS for 7- to 11-year-olds (n ¼ 511 per cohort). For 5- to 6-year-
olds in the small-particle ICS cohort, the adjOR for achieving risk-
domain asthma control was 2.00 (95% CI, 1.21-3.29) and for
achieving overall control was 1.66 (95% CI, 1.11-2.46) compared
with standard sizeeparticle ICS; the corresponding odds ratios for
7- to 11-year-olds were 1.25 (95% CI, 0.85-1.83) and 1.19 (95%
CI, 0.91-1.57). The severe exacerbation adjRR for the small-
particle ICS cohort relative to the standard sizeeparticle ICS
cohort was 0.51 (0.23-1.10) and the clinical exacerbation rate ratio
was 0.48 (0.30-0.77) for 5- to 6-year-olds; the corresponding
adjRRs for 7- to 11-year-olds were 0.76 (0.45-1.28) and 0.87
(0.60-1.25), respectively.
Baseline asthma severity was greater among 5- to 6-year-olds
initiating ICS (data not shown); therefore, we hypothesized that
better outcomes with small-particle ICS in this cohort were related to
baseline severity rather than age. However, the subanalysis of out-
comes split by asthma severity (0 or 1 baseline exacerbations)
indicated better results for children with less severe asthma
(Table E3). Further exploration of results for risk-domain asthma
control by outcome-year ICS dose indicated greater variation in re-
sults for 5- to 6-year-olds (compared with 7-11-year-olds) and greater
variation in the standard sizeeparticle ICS cohort (Figure E6).
Results of the subanalysis including children with no rhinitis
diagnosis or prescription for nasal spray (unmatched cohorts)
were reﬂective of the main analysis results: the odds ratios
remained consistent, although with smaller patient numbers theodds ratio for risk-domain asthma control became statistically
nonsigniﬁcant (Table E3).
Analysis 2: Unmatched versus matched baselines
and results
For analysis 2, the unmatched ICS step-up cohort, as compared
with both add-on LABA cohorts, received a lower baseline ICS
dose and included more children with asthma control and fewer
children with severe exacerbations during baseline (data not
shown). After matching, the matched add-on LABA cohorts had
(similar to the ICS step-up cohort) less severe asthma than did the
unmatched cohorts (67%-70% with baseline asthma control vs
58% of the unmatched add-on LABA cohorts).
During the outcome year, a signiﬁcantly greater percentage of
unmatched patients in the ICS step-up cohort experienced
asthma control and treatment stability as compared with both
add-on LABA cohorts (data not shown). Unadjusted exacerba-
tion results were similar for unmatched ICS step-up and ICS/
LABA combination cohorts but better for the unmatched ICS
step-up than for the separate ICS þ LABA cohort.
Analysis 2: ICS dose step-up versus add-on LABA as
separate inhaler
Several minor differences remained at baseline after 1:2
matching of the small-particle ICS dose step-up (n ¼ 276) and
separate ICS þ LABA (n ¼ 552) cohorts (Tables E4 and E6).
Children in the ICS dose step-up cohort recorded fewer exac-
erbations during the baseline year than did children in the
separate ICS þ LABA cohort (Table E6).
Median (interquartile range) ICS doses prescribed at the index
date were 200 mg/d (200-400 mg/d) for the ICS dose step-up and
100 mg/d (100-200 mg/d) for the separate ICS þ LABA cohort
(P < .001 for the comparison). Change in therapy was signiﬁ-
cantly more common, and the total b2-agonist coverage (LABA
plus SABA) was signiﬁcantly greater in the separate ICS þ LABA
cohort (Table E5). Figure E7, B, depicts coverage by time period
for each cohort.
During the outcome year, children stepping up their ICS
therapy with small-particle ICS had signiﬁcantly higher odds of
treatment stability, after adjustments for residual confounding
factors, than did children remaining on the same dose but adding
a separate LABA; odds of asthma control and exacerbation rates
were comparable between cohorts (Figure E8; Table E7).
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Respiratory patients
in the GPRD & OPCRD
n=1,540,877
Patients prescribed 
any ICS inhalers
n=705,913 Excluded:
-not aged 5–11 years and not initiating ICS as 
small-particle beclomethasone or 
fluticasone by pMDI (n=694,785)
Inclusion Criteria:
Patients aged 5–11 years initiating 
ICS as small-particle beclomethasone 
or fluticasone by pMDI
Matching criteria applied:
-same sex
-same age
-baseline mean SABA dose (0, 
1–100, 101–200, >200 
μg/day)
-baseline year no. severe 
exacerbations (0, 1, ≥2)
-baseline no. asthma 
consultations without oral 
steroid prescription (0,1,≥2)
-year of index date ±4 years
Randomize matching patients 1:1*
*Software used to randomly pick 
unique matched patients
Excluded: 
-not registered at practice for study period 
(SP-BDP n=852; FP n=1432)
-prescribed FDC therapy during baseline 
or on index date (SP-BDP n=1221; FP 
n=3590)
-diagnosis of chronic respiratory disease 
other than asthma (FP n=1)
-no evidence of asthma (SP-BDP 
n=1021; FP n=1065)
-maintenance oral steroids during 
baseline (SP-BDP n=60; FP n=49)
-initiate ICS on multiple prescriptions (SP-
BDP n=25; FP n=50)
-duplicated in GPRD or OPCRD (SP-BDP 
n=33; FP n=77)Eligible patients aged 5–11 with 
asthma initiating ICS therapy as:
SP-beclomethasone n=1025
Fluticasone n=1629
Total lost on matching:
SP-beclomethasone n=100
Fluticasone n=344
Total matched patients included
1:1 uniquely matched pairs:
Small-particle beclomethasone n=797
Fluticasone n=797
Excluded:
Patients not on any ICS therapy 
(n=834,964)
Double matches lost on 
randomization 1:1:
SP-beclomethasone n=128
Fluticasone n=488
Patients aged 5–11 prescribed 
small-particle beclomethasone n=4237
or fluticasone n=7893
FIGURE E1. Initiation population: patient selection and matching (analysis 1). Patients in the 2 treatment cohorts were matched on
clinically and demographically significant characteristics. FDC, Fixed-dose combination ICS/LABA; FP, fluticasone propionate; GPRD,
General Practice Research Database; OPCRD, Optimum Patient Care Research Database; SP-BDP, small-particle beclomethasone
dipropionate.
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Respiratory patients
in the GPRD & OPCRD
n=1,540,877
Patients prescribed 
any ICS inhalers
n=706,913
Excluded:
-no prior prescription (n=29,341) or no current 
prescription (n=548,082) for SP-BDP or 
fluticasone by pMDI
-prescribed lower, same, or <50% increase in 
ICS dose (n=92,962)
-multiple prescriptions on the index date 
(n=5973)
Inclusion Criteria:
Patients prescribed a ≥50% 
increase in ICS dose as SP-BDP or 
fluticasone by pMDI
Matching criteria applied:
-same sex
-same age
-last ICS dose before index 
date (1–100, 101–300, >300 
μg/day)
-baseline year no. severe 
exacerbations (0, 1, 2, ≥3)
-risk-domain asthma control 
status 
(controlled/uncontrolled)
-baseline mean SABA dose (0, 
1–200, >200 μg/day)
-baseline no. asthma 
consultations without oral 
steroid prescription (0, 1, ≥2)
-year of index date ±4 years Randomize matching patients 1:1*
*Software used to randomly pick 
unique matched patients
Excluded: 
-not aged 5–11 years at index date 
(n=27,223)
-not registered at practice for study 
period (n=435)
-prescribed FDC therapy during 
baseline or on index date (n=14)
-no evidence of asthma (n=69)
-maintenance oral steroids during 
baseline (n=89)
-prescribed ICS on multiple 
prescriptions (n=575)
-duplicated in GPRD or OPCRD 
(n=209)Eligible patients aged 5–11 
stepping up ICS therapy as:
Small-particle beclomethasone n=294
Fluticasone n=1647
Total lost on matching:
Small-particle beclomethasone n=77
Fluticasone n=1106
Total matched patients included
1:1 uniquely matched pairs:
Small-particle beclomethasone n=206
Fluticasone n=206
Excluded:
Patients not on any ICS therapy 
(n=833,964)
Double matches lost on 
randomization 1:1:
Small-particle beclomethasone n=11
Fluticasone n=335
Patients prescribed ≥50% dose increase of 
small-particle beclomethasone and/or 
fluticasone as single script: 
n=30,555
FIGURE E2. Step-up population: patient selection and matching (analysis 1). Patients in the 2 treatment cohorts were matched on
clinically and demographically significant characteristics. FDC, Fixed-dose combination ICS/LABA; FP, fluticasone propionate; GPRD,
General Practice Research Database; OPCRD, Optimum Patient Care Research Database; Script, prescription; SP-BDP, small-particle
beclomethasone dipropionate.
J ALLERGY CLIN IMMUNOL PRACT
VOLUME 3, NUMBER 5
VAN AALDEREN ETAL 731.e6
Respiratory patients in the GPRD & OPCRD
1) SP-BDP with prior ICS script n=1,146,757
or 2) ICS script with no prior LABA n=689,076
SP-BDP dose increase n=34,509
or ICS + LABA n=240,581
ICS/LABA cohort exclusions:
-not registered at practice for study period 
(n=2960)
-no current asthma Rx (n=1044)
-separate LABA, ICS, or FDC or multiple 
scripts on IPD (n=7758)
-increased ICS dose at IPD (n=2979)
-maintenance oral steroids during 
baseline (n=7)
-COPD or other chronic (n=10)
-duplicated in GPRD or OPCRD (n=290)
Inclusion 
Criteria:
1) ≥50% ICS 
dose increase 
as SP-BDP by 
pMDI or BAI or
2) LABA script 
as add-on or 
FDC
Matching criteria applied:
-same sex
-same age
-last ICS dose before index 
date (1–50, 51–100, 101–
200, 201–300, 301–400, 
>400 μg/day)
-risk-domain asthma control 
status 
(controlled/uncontrolled)
-baseline mean SABA dose 
(0, 1–200, 201–400, >400 
μg/day)
-baseline no. asthma 
consultations without OCS 
prescription (0, 1, ≥2)
Randomize matching patients 1:1*
*Software used to randomly pick 
unique matched patients
SP-BDP cohort exclusions: 
-on DPI baseline (n=60)
-not registered at practice for study 
period (n=448)
-LABA or FDC script during baseline or 
on IPD (n=98)
-no current asthma Rx (n=72)
-maintenance OCS baseline (n=0)
-additional ICS dose increases (n=41)
-COPD or other (n=3)
-duplicated in GPRD or OPCRD (n=53)
Eligible patients aged 5–11 stepping 
up asthma therapy as:
SP-BDP increased dose n=458
ICS/LABA combination n=1440
Total lost on matching:
SP-BDP n=214
ICS/LABA n=971
Total matched patients included
1:1 uniquely matched pairs:
Small-particle beclomethasone n=185
ICS/LABA combination inhaler n=185
Double matches lost on 
randomization 1:1:
SP-BDP n=55
ICS/LABA n=284
SP-BDP cohort key 
inclusions: 
-no LABA inhaler baseline
-on pMDI or BAI
-on current asthma Rx
-no COPD/chronic resp
SP-BDP dose increase n=1233
or ICS + LABA n=16,489
Excluded <5 or >11 years old
-SP-BDP (n=33,276)
-ICS/LABA (n=224,092)
ICS/LABA cohort key 
inclusions:
-switch to FDC inhaler
-no change in ICS dose
FIGURE E3. Small-particle ICS dose step-up versus add-on LABA in ICS/LABA combination inhaler: patient selection and matching
(analysis 2). Patients in the 2 treatment cohorts were matched on clinically and demographically significant characteristics. BAI, Breath-
actuated inhaler; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FDC, fixed-dose combination ICS/LABA; GPRD,
General Practice Research Database; IPD, index prescription date; OCS, oral corticosteroid; OPCRD, Optimum Patient Care Research
Database; Rx, therapy; Script, prescription; SP-BDP, small-particle beclomethasone dipropionate.
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Respiratory patients in the GPRD & OPCRD
1) SP-BDP with prior ICS script n=1,146,757
or 2) ICS script with no prior LABA n=689,076
SP-BDP dose increase n=34,509
or ICS + LABA n=240,581
Separate ICS+LABA cohort exclusions:
-not registered at practice for study period 
(n=2960)
-no current asthma Rx (n=1044)
-FDC script on IPD (n=4851)
-LABA by DPI (n=1226)
-change to LABA pre-1998 (n=1318)
-change in ICS dose at IPD (n=872)
-maintenance OCS baseline (n=24)
-COPD or other chronic (n=20)
-duplicated in GPRD or OPCRD (n=550)
Inclusion 
Criteria:
1) ≥50% ICS 
dose increase 
as SP-BDP by 
pMDI or BAI or
2) LABA script 
as add-on or 
FDC
Matching criteria applied:
-same sex
-same age
-last ICS dose before index 
date (1–50, 51–100, 101–
200, 201–300, 301–400, 
>400 μg/day)
-risk-domain asthma control 
status 
(controlled/uncontrolled)
-baseline mean SABA dose 
(0, 1–200, 201–400, >400 
μg/day)
-baseline no. asthma 
consultations without OCS 
prescription (0, 1, ≥2)
Randomize matching patients 1:2*
*Software used to randomly pick 
unique matched patients
SP-BDP cohort exclusions: 
-on DPI baseline (n=60)
-not registered at practice for study 
period (n=448)
-LABA or FDC script during baseline or 
on IPD (n=98)
-no current asthma Rx (n=72)
-maintenance OCS baseline (n=0)
-additional ICS dose increases (n=41)
-COPD or other (n=3)
-duplicated in GPRD or OPCRD (n=53)
Eligible patients aged 5–11 stepping 
up asthma therapy as:
SP-BDP increased dose n=458
Separate ICS+LABA inhalers n=3624
Total lost on matching:
SP-BDP n=65
ICS/LABA n=2291
Total matched patients included
1:2 uniquely matched pairs:
Small-particle beclomethasone n=276
Separate ICS+LABA inhalers n=552
Double matches lost on 
randomization 1:2:
SP-BDP n=113
Separate ICS+LABA n=781
SP-BDP cohort key 
inclusions: 
-no LABA inhaler baseline
-on pMDI or BAI
-on current asthma Rx
-no COPD/chronic resp
SP-BDP dose increase n=1233
or ICS + LABA n=16,489
Excluded <5 or >11 years old
-SP-BDP (n=33,276)
-ICS+LABA (n=224,092)
Separate ICS+LABA cohort 
key inclusions:
-add-on LABA
-no change in ICS dose
FIGURE E4. Small-particle ICS dose step-up versus add-on LABA to ICS in separate inhalers: patient selection and matching (analysis 2).
Patients in the 2 treatment cohorts were matched on clinically and demographically significant characteristics. BAI, Breath-actuated
inhaler; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FDC, fixed-dose combination ICS/LABA; GPRD, Gen-
eral Practice Research Database; IPD, index prescription date; OCS, oral corticosteroid; OPCRD, Optimum Patient Care Research
Database; Rx, therapy; Script, prescription; SP-BDP, small-particle beclomethasone dipropionate.
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FIGURE E5. ICS dose for matched cohorts as prescribed on the index date for (A) the initiation population and (B) the step-up population.
Differences in prescribed doses between small-particle ICS and standard sizeeparticle ICS cohorts were statistically significant
(P < .001).
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FIGURE E6. Probability of achieving risk-domain asthma control during the outcome year for children in the initiation population. Prob-
ability categorized by (A) age group and (B) treatment cohort, categorized by ICS daily dose exposure (ie, prescribed ICS dose divided by
365). Standard SP, Standard sizeeparticle.
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FIGURE E7. Total b2-agonist load comparing small-particle ICS dose step-up versus add-on LABA to ICS in (A) fixed-dose combination
inhaler with ICS and (B) separate inhalers. Hours covered per 24 hours. FDC, fixed-dose combination.
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FIGURE E8. AdjORs and adjRRs comparing step-up with increased dose of small-particle ICS versus add-on LABA as separate inhaler
with ICS. (For details of confounding factors examined, please see above in Online Repository.) LRTI, Lower respiratory tract infection;
NSAIDs, nonsteroidal anti-inflammatory drugs. Adjusted for the following confounders: *Number of asthma consultations, number of
acute courses of oral corticosteroids, number of antibiotic prescriptions for LRTI. †Asthma diagnosis, prescriptions for NSAIDs, number of
acute courses of oral corticosteroids, number of antibiotic prescriptions for LRTI, controller-to-reliever ratio. zNumber of asthma con-
sultations, number of acute courses of oral corticosteroids, controller-to-reliever ratio. xAsthma diagnosis, number of primary care con-
sultations, number of acute courses of oral corticosteroids, number of antibiotic prescriptions for LRTI, inpatient admission for lower
respiratory tract-related reasons. #Controller-to-reliever ratio, definite plus probable asthma-related hospitalizations.
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TABLE E1. More baseline characteristics of children in the small-particle ICS and standard SP ICS cohorts (analysis 1)
Characteristic
Initiation population Step-up population
Small-particle ICS
(n [ 797)
Standard SP ICS
(n [ 797) P value*
Small-particle ICS
(n [ 206)
Standard SP ICS
(n [ 206) P value*
Socioeconomic score† available 778 (97.6) 786 (98.6) 203 (98.5) 205 (99.5)
Mean  SD 20.8  14.9 21.7  16.2 .43 22.2  16.0 21.0  15.2 .49
Median (IQR) 16.2 (10.2-27.0) 16.2 (10.5-27.2) 17.1 (10.4-29.3) 16.3 (10.5-25.0)
BMI (kg/m2), mean  SDz 17.4  3.4 17.4  3.7 .83 17.0  2.7 16.8  2.9 1.0
Years since ﬁrst asthma code, median (IQR) 0.6 (0.0-3.8) 0.6 (0.0-4.0) .46 3.0 (1.4-5.3) 3.7 (1.7-5.3) .075
Database Read code for asthma 786 (98.6) 785 (98.5) .83 202 (98.1) 203 (98.5) .71
Patients with PEF reading at baseline 114 (14.3) 143 (17.9) 79 (38.3) 67 (32.5)
Mean  SD %predicted PEF 101  26.4 101  29.2 .82 115  27.8 102  28.1 .061
1 prescription in the previous 12 mo
Nonsteroidal anti-inﬂammatory drug 44 (5.5) 49 (6.1) .60 14 (6.8) 13 (6.3) .85
Acetaminophen 99 (12.4) 132 (16.6) .017 38 (18.4) 39 (18.9) .90
Clinical exacerbations
0 659 (82.7) 661 (82.9) .75 161 (78.2) 163 (79.1) .80
1 105 (13.2) 106 (13.3) 35 (17) 32 (15.5)
2 33 (4.1) 30 (3.8) 10 (4.9) 11 (5.3)
Asthma prescriptions, median (IQR) 2 (0-3) 2 (0-4) .60 6 (4-11) 9 (5-15) <.001
All primary care consultations, median (IQR) 4 (2-6) 4 (2-6) .28 4 (3-8) 5 (3-9) .03
GP consultation for LRTI requiring antibiotic
0 698 (87.6) 706 (88.6) .53 187 (90.8) 188 (91.3) .76
1 99 (12.4) 91 (11.4) 19 (9.2) 18 (8.7)
BMI, Body mass index; IQR, interquartile range; LRTI, lower respiratory tract infection; PEF, peak expiratory ﬂow; standard SP, standard sizeeparticle.
Data are n (%) unless otherwise noted.
*Matched cohorts were compared using conditional logistic regression.
†The socioeconomic status score for practices used in the analyses was that assigned by local postcodes using the Index of Multiple Deprivation as a proxy measure (https://
www.gov.uk/government/collections/english-indices-of-deprivation). A high score indicates a high level of deprivation, whereas the least deprived areas have a low score.
zRecorded BMI data were available for 287 (36%) and 286 (36%) children in small-particle ICS and standard SP ICS initiation cohorts, respectively, and for 91 (44%) and 103
(50%) children in small-particle ICS and standard SP ICS step-up cohorts, respectively.
TABLE E2. Asthma therapy during the outcome year for matched cohorts prescribed small-particle ICS or standard SP ICS for first-line or
step-up therapy (analysis 1)
Outcome
Initiation population Step-up population
Small-particle ICS
(n [ 797)
Standard SP ICS
(n [ 797) P value*
Small-particle ICS
(n [ 206)
Standard SP ICS
(n [ 206) P value*
Spacer device prescribed 397 (49.8) 340 (42.7) .004 95 (46.1) 73 (35.4) .034
Number of ICS inhalers, median (IQR)† 2 (1-4) 3 (2-6) <0.001 4 (3-7) 6 (4-9) <.001
Two or more ICS inhalers 531 (66.6) 621 (77.9) <0.001 190 (92.2) 201 (98.6) <.001
Any prescribed change in therapy 89 (11.2) 157 (19.7) <.001 30 (14.6) 31 (15.0) .88
Increase in ICS dose 57 (7.2) 91 (11.4) .004 12 (5.8) 8 (3.9) .35
Any additional therapyz 46 (5.8) 87 (10.9) <.001 22 (10.7) 28 (13.6) .34
Fluticasone-salmeterol 13 (1.6) 35 (4.4) .002 5 (2.4) 16 (7.8) .023
Budesonide-formoterol 2 (0.3) 1 (0.1) .57 3 (1.5) 1 (0.5) .34
LABA 19 (2.4) 39 (4.9) .010 10 (4.9) 9 (4.4) .81
Leukotriene receptor antagonistx 20 (2.5) 26 (3.3) .37 8 (3.9) 5 (2.4) .37
Standard SP, Standard sizeeparticle.
Data are n (%) unless otherwise noted.
*Conditional logistic regression.
†Number of ICS inhalers prescribed during the outcome year in addition to the index prescription. ICS inhaler durations ranged from 30 d (eg, for Flixotide) to 50 d (eg, for
QVAR).
zChange in therapy and additional therapy could be at any time during the outcome year, and children could have had more than 1.
xMontelukast is the only leukotriene receptor antagonist licensed in the United Kingdom.
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TABLE E3. Summary of matched spacer subanalysis and unmatched full analysis and subanalyses for the initiation population: small-
particle ICS or standard SP ICS comparison
Initiation population
AdjOR/RR (95% CI) for small-particle ICS relative to standard SP ICS (1.00)
Matched cohort analysis Unmatched analyses
Spacer subanalysis* Full unmatched No rhinitis diagnosis or therapy 0 Exacerbations ‡1 Exacerbations
Sample size
Small-particle ICS 465 1058 858 911 147
Standard SP ICS 465* 1706 1281 1487 219
Risk-domain asthma control 1.81 (1.24-2.65)† 1.32 (1.05-1.65)† 1.31 (0.99-1.72)† 1.35 (1.04-1.75)† 1.03 (0.64-1.64)†
Overall asthma control 1.49 (1.12-2.00)z 1.28 (1.08-1.51)z 1.25 (1.02-1.53)z 1.27 (1.06-1.53)z 1.22 (0.79-1.89)z
Treatment stability 1.80 (1.32-2.46)x 1.80 (1.50-2.16)x 1.68 (1.36-2.06)x 1.97 (1.61-2.41)x 1.21 (0.79-1.86)x
Severe exacerbations 0.53 (0.29-0.98)# 0.63 (0.47-0.84)# 0.67 (0.48-0.94)# 0.52 (0.34-0.77)# 0.88 (0.53-1.45)#
Clinical exacerbations 0.55 (0.38-0.79)
ˇ
0.77 (0.62-0.95)
ˇ
0.71 (0.55-0.91)
ˇ
0.71 (0.55-0.93)
ˇ
0.85 (0.54-1.32)
ˇ
LRTI hospitalizations 0.71 (0.23-2.25)†† 0.90 (0.43-1.88)†† 1.06 (0.49-2.27)†† — —
IQR, Interquartile range; LRTI, lower respiratory tract infection; standard SP, standard sizeeparticle.
*All children in the standard SP ICS cohort and 319 (68.6%) children in the small-particle ICS cohort were prescribed a spacer device during baseline and/or outcome year.
Spacer subanalysis adjusted for:
†GP consultation for LRTI requiring antibiotics. zNumber of prescriptions for asthma or allergies. xBaseline LABA use and number of noneasthma-related consultations.
#Mean SABA daily dose, outpatient department attendance for lower respiratory reasons, and year of index date.
ˇ
GP consultation for LRTI requiring antibiotics and year of
index date. ††No signiﬁcant effects.
Full unmatched analysis adjusted for:
†Mean SABA daily dose, age, number of severe exacerbations. zMean SABA daily dose, sex, asthma control status, rhinitis diagnosis and/or therapy. xAsthma control status,
mean SABA daily dose, use of LABA. #Mean SABA daily dose, number of severe exacerbations.
ˇ
Number of severe exacerbations, oral candidiasis, age, rhinitis diagnosis and/
or therapy. ††Inpatient admissions for lower respiratory reasons (including vague).
No rhinitis subanalysis adjusted for:
†Age, year of index date, mean SABA daily dose, number of acute oral corticosteroid courses. zMean SABA daily dose, year of index date, number of acute oral corticosteroid
courses. xMean SABA daily dose, LABA use, number of acute oral corticosteroid courses, number of noneasthma-related consultations. #Year of index date, LABA use, mean
SABA daily dose, number of acute oral corticosteroid courses.
ˇ
Age, year of index date, mean SABA daily dose, number of acute oral corticosteroid courses, number of
consultations for LRTI. ††Year of ﬁrst asthma coding, mean SABA daily dose, baseline inpatient admissions for lower respiratory events.
0 exacerbations subanalysis adjusted for:
†Mean SABA daily dose, age, rhinitis diagnosis and/or therapy. zAsthma control status, mean SABA daily dose, sex, rhinitis diagnosis and/or therapy, asthma diagnosis.
xAsthma control status, mean SABA daily dose. #Mean SABA daily dose, rhinitis diagnosis and/or therapy. ˇOral candidiasis, rhinitis diagnosis and/or therapy, number of
consultations for LRTI requiring antibiotic.
1 exacerbations subanalysis adjusted for:
†Age. zMean SABA daily dose. xNo signiﬁcant effects. #Sex, number of severe exacerbations. ˇNumber of severe exacerbations.
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TABLE E4. More baseline characteristics of children in the small-particle ICS step-up and add-on LABA cohorts (analysis 2)
Characteristic
ICS step-up vs ICS/LABA combination ICS step-up vs separate ICS D LABA
ICS dose step-up
(n [ 185)
ICS/LABA combination
(n [ 185) P value*
ICS dose step-up
(n [ 276)
Separate ICS D LABA
(n [ 552) P value*
BMI (kg/m2), mean  SD† 18.0  4.2 17.0  3.4 .79 17.5  3.3 17.3  3.8 .57
Year of study index prescription, median (IQR) 2005 (2002-2007) 2006 (2004-2007) <.001 2005 (2002-2007) 2004 (2002-2006) <.001
Years since ﬁrst asthma code, median (IQR) 3.4 (1.6-6.0) 3.3 (1.2-5.5) .36 3.1 (1.3-5.4) 3.6 (1.8-5.5) .038
Database code for asthma 177 (95.7) 177 (95.7) 1.0 265 (96.0) 543 (98.4) .047
1 prescription in the previous 12 mo
Nonsteroidal anti-inﬂammatory drug 12 (6.5) 12 (6.5) 1.0 26 (9.4) 29 (5.3) .019
Acetaminophen 33 (17.8) 34 (18.4) .90 56 (20.3) 106 (19.2) .71
Recorded %predicted PEF 83 (44.9) 82 (44.3) — 111 (40.2) 249 (45.1) —
%predicted PEF, mean  SD 106  29 104  31 .25 108  30 110  28 .96
Clinical exacerbations
0 131 (70.8) 136 (73.5) .42 188 (68.1) 376 (68.1) .26
1 39 (21.1) 33 (17.8) 60 (21.7) 108 (19.6)
2 9 (4.9) 12 (6.5) 20 (7.2) 45 (8.2)
3 6 (3.2) 4 (2.2) 8 (2.9) 23 (4.2)
Asthma prescriptions, median (IQR) 4 (3-6) 5 (3-7) .29 4 (2-7) 4 (3-7) .090
All primary care consultations, median (IQR) 5 (3-8) 5 (3-8) .10 5 (3-8) 5 (3-9) .049
GP consultation for LRTI requiring antibiotic
0 159 (85.9) 167 (90.3) .12 236 (85.5) 496 (89.9) .17
1 26 (14.1) 18 (9.7) 40 (14.5) 56 (10.1)
BMI, Body mass index; IQR, interquartile range; LRTI, lower respiratory tract infection; PEF, peak expiratory ﬂow.
Data are n (%) except otherwise indicated.
*Matched cohorts were compared using conditional logistic regression.
†Recorded data were available for BMI for 89 (48.1%) and 86 (46.5%) in ICS step-up and ICS/LABA combination cohorts, respectively, and for 127 (46.0%) and 265 (48.0%)
in ICS step-up and separate ICS þ LABA cohorts, respectively.
TABLE E5. Asthma therapy during the outcome year for matched cohorts in the small-particle ICS step-up and add-on LABA cohorts
(analysis 2)
Outcome
ICS step-up vs ICS/LABA combination ICS step-up vs separate ICS D LABA
ICS dose
step-up
(n [ 185)
ICS/LABA
combination
(n [ 185) P value*
ICS dose
step-up
(n [ 276)
Separate
ICS D LABA
(n [ 552) P value*
Spacer device prescribed 66 (35.7) 54 (29.2) .18 112 (40.6) 229 (41.5) .81
No. ICS or ICS/LABA inhalers, median (IQR)† 4 (2-6) 6 (4-8) <.001 4 (2-6) 4 (2-7) .65
Three or more ICS inhalers 130 (70.3) 160 (86.5) <.001 205 (74.3) 388 (74.2) .44
Median (IQR) b2-agonist coverage (h)z 2.2 (1.1-4.4) 15.7 (10.1-23.6) <.001 2.2 (1.1-4.4) 9.1 (5.3-16.4) <.001
Change in b2-agonist coverage (h) 0 (0.6 to 1.6) 13.8 (7.9-21.4) <.001 0.5 (0.5 to 1.6) 6.6 (3.1-13.4) <.001
Any prescribed change in therapyx 29 (15.7) 43 (23.2) .002 44 (15.9) 166 (30.1) <.001
Increase in ICS dose 5 (2.7) 30 (16.2) <.001 9 (3.3) 125 (22.6) <.001
Any additional therapy 28 (15.1) 18 (9.7) .10 39 (14.1) 111 (20.1) .036
Fluticasone-salmeterol 11 (5.9) 0 (0) NA 13 (4.7) 74 (13.4) <.001
Budesonide-formoterol 2 (1.1) 0 (0) NA 2 (0.7) 13 (2.4) .12
Long-acting b2-agonist 12 (6.5) 1 (0.5) .017 20 (7.2) 0 (0) .012
Leukotriene receptor antagonistjj 8 (4.3) 17 (9.2) .058 11 (4.0) 40 (7.2) .073
DPI, Dry powder inhaler; IQR, interquartile range; NA, not applicable.
Data are n (%) unless otherwise stated.
*Conditional logistic regression.
†Number of ICS or ICS/LABA inhalers prescribed during the outcome year in addition to the index prescription.
zTotal b2-agonist coverage (SABA þ LABA) was calculated as SABA 2 puffs lasting 4 h plus LABA 2 puffs via pMDI or 1 puff via DPI lasting 12 h. Change was the
difference between the baseline and outcome years.
xChange in therapy and additional therapy could be at any time during the outcome year; therefore, children could have had more than 1 change/additional therapy.
jjMontelukast is the only leukotriene receptor antagonist licensed in the United Kingdom.
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TABLE E6. Baseline characteristics of children comparing ICS
step-up and separate ICS þ LABA cohorts (analysis 2)
Characteristic
ICS step-up vs separate ICS D LABA
ICS dose
step-up
(n [ 276)
Separate
ICS D LABA
(n [ 552) P value*
Sex: male† 170 (61.6) 340 (61.6) NA
Age at index date (y),
mean  SD†
7.7  2.0 7.7  2.0 NA
Recorded comorbidityz
Possible atopy 214 (77.5) 442 (80.1) .39
Rhinitis diagnosis/Rx 61 (22.1) 142 (25.7) .26
Eczema diagnosis/Rx 199 (72.1) 416 (75.4) .32
Preschool wheeze
diagnosis
113 (40.9) 249 (45.1) .25
Preschool asthma
diagnosis/Rx
147 (53.3) 326 (59.1) .11
Risk-domain asthma control† 185 (67.0) 370 (67.0) NA
Spacer device prescribed 110 (39.9) 230 (41.7) .61
Mean daily SABA dose (mg/d)†
0-100 50 (18.1) 86 (15.6)
101-200 100 (36.2) 214 (38.8) .35
201-400 83 (30.1) 166 (30.1)
401-800 35 (12.7) 70 (12.7)
>800 8 (2.9) 16 (2.9)
Median (IQR) daily ICS dose
(mg/d)x
55 (27-110) 55 (27-110) .32
Last ICS dose before the index
date (mg/d)†,x
1-50 6 (2.2) 12 (2.2) NA
51-100 195 (70.7) 390 (70.7)
101-200 75 (27.2) 147 (26.6)
Severe exacerbations
0 215 (77.9) 403 (73.0) .062
1 40 (14.5) 102 (18.5)
2 15 (5.4) 30 (5.4)
3 6 (2.2) 17 (3.1)
Asthma consultation/no oral corticosteroids†
0 96 (34.8) 192 (34.8) .34
1 89 (32.2) 178 (32.2)
2 55 (19.9) 99 (17.9)
3 36 (13.0) 83 (15.0)
IQR, Interquartile range; NA, not applicable; Rx, therapy.
*Matched cohorts were compared using conditional logistic regression.
†Matching variable (please see above in Online Repository text for details).
zPossible atopy was deﬁned as any 1 or more of the following: recorded rhinitis
diagnosis, rhinitis therapy, eczema diagnosis, eczema therapy. Preschool wheeze was
captured through database coding; concomitant rhinitis, eczema, and preschool
asthma were captured through database-coded diagnosis or therapy for same. Pre-
school was deﬁned as age 1 to 3 y.
xThe doses of ICS were standardized to equivalence with small-particle beclome-
thasone and ﬂuticasone; thus, doses of large-particle beclomethasone and budesonide
were halved.
TABLE E7. Outcome-year results for matched cohorts comparing
small-particle ICS step-up and separate ICS þ LABA cohorts
(analysis 2)
Outcome
ICS step-up vs separate ICS D LABA
ICS dose
step-up
(n [ 276)
Separate
ICS D LABA
(n [ 552)
Risk-domain asthma control 215 (77.9) 404 (73.2)
Treatment stability 191 (69.2) 303 (54.9)
Severe exacerbation
0 232 (84.1) 447 (81.0)
1 33 (12.0) 76 (13.8)
2 11 (4.0) 29 (5.3)
Clinical exacerbation
0 218 (79.0) 412 (74.6)
1 42 (15.2) 97 (17.6)
2 16 (5.8) 43 (7.8)
Disaggregated results of
composite measures P value*
1 asthma-related hospitalization 2 (0.7) 2 (0.4) .49
1 acute course of oral
corticosteroids
42 (15.2) 100 (18.1) .39
1 GP consultation for LRTI
requiring antibiotic
26 (9.4) 55 (10.0) .65
Mean >2 puffs daily SABA 165 (59.8) 303 (54.9) .37
Increase in ICS dose or additional
therapy
44 (15.9) 166 (30.1) <.001
LRTI, Lower respiratory tract infection.
Data are n (%) unless otherwise stated.
*Conditional logistic regression.
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